Clinical Trial Update: Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial investigating Pseudovax, a cancer vaccine for pseudomyxoma peritonei, is currently recruiting at Oslo University Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pseudomyxoma Peritonei

Drugs mentioned

• Pseudovax

Snippet

Sponsor: Oslo University Hospital | Conditions: Pseudomyxoma Peritonei | EARLY_Phase 1 | Status: RECRUITING